Transcutaneous CO₂ Therapy in Recurrent Hard-to-Heal Diabetic Foot Ulcers
Key facts
- Who runs it
- University Medical Centre Ljubljana
- Where
- Slovenia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 1 Sept 2024
- Ended
- 30 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- transcutaneous application of gaseous CO2 on lower part of the body
- Record updated
- 24 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- diabetes mellitus type 1 or 2
- recurrent hard to heal DFU
Who cannot take part
- malignant diseases
- infected ulcer at baseline
- KOPD stage IV
- CKD stage IV
- pregnancy
- inability to comply with visits
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Recurrent and hard-to-heal diabetic foot ulcers (DFUs) represent a clinically challenging subgroup with delayed closure and frequent non-response to standard of care (SOC). Impaired local perfusion and superficial tissue hypoxia, commonly attributed to microcirculatory dysfunction, are proposed contributors to impaired wound-bed progression and prolonged healing trajectories in diabetes. Transcutaneous gaseous carbon dioxide (CO₂) therapy is a non-invasive adjunct intervention with a mechanistic rationale to modulate local microcirculation and tissue oxygenation; however, controlled clinical evidence in recurrent, hard-to-heal DFUs remains limited. This prospective, randomized, controlled, open-label, parallel-group clinical investigation compares transcutaneous CO₂ therapy plus SOC versus SOC alone over 4 weeks. The primary objective is to determine whether the proportion of completely healed DFUs at Week 4 differs between groups under a predefined healing confirmation procedure. Key secondary objectives include quantifying changes in superficial tissue oxygenation (StO₂) using hyperspectral imaging and assessing pain intensity (NPRS). Supportive outcomes include ulcer area reduction metrics and wound-bed appearance in unhealed.
The 2 groups in the trial
- Standard of care + CO2 therapyTreatment being tested
Standard of care (3 times weekly) + transcutaneous gaseous CO2 therapy 20 times (every weekday for 50 minutes)
Treatment: transcutaneous application of gaseous CO2 on lower part of the body
- Standard of careNo study treatment, for comparison
Standard of care (3 times weekly)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 24 February 2026